Illumina/TruSeq PE Cluster Kit v3-cBot-HS/PE-401-3001/1 Ea

產(chǎn)品編號(hào)： PE-401-3001   美  元  價(jià)： $6200.00           品      牌： Illumina

產(chǎn)       地： 美國(guó)                 公 司： Illumina, Inc.           產(chǎn)品分類(lèi)： 分子類(lèi)>二代測(cè)序>簇生成和測(cè)序試劑公司分類(lèi)： Cluster Generation & Sequencing Reagents   Size: 1 Ea

Illumina公司創(chuàng)立于1998年4月，是遺傳變異和生物學(xué)功能分析領(lǐng)域的優(yōu)秀的產(chǎn)品、技術(shù)和服務(wù)供應(yīng)商。通過(guò)幫助客戶(hù)加快實(shí)現(xiàn)生物信息的采集、分析和應(yīng)用，來(lái)改善人類(lèi)健康。

Sequencing Kits/ Microarray Kits/Informatics Products/ Clinical Research Products/In Vitro Diagnostic/ Products/Molecular Biology Reagents/ Accessory Products

Illumina 測(cè)序試劑盒 PE-401-3001

Product Highlights:

For use with HiSeq 2500, HiSeq 2000, HiSeq 1000, and HiScanSQ instruments with the cBot System, the TruSeq PE (Paired-End) Cluster Kit v3-cBot-HS provides reagents that bind samples to complementary adapter oligos on paired-end flow cells. These enable copying of the DNA strand after the first sequencing run, and the copied strand is used to sequence the other fragment end.

This kit enables cluster amplification on the cBot System. DNA library samples are bound to complementary adapter oligos grafted on the surface of the flow cell. The templates are copied from the hybridized primer by 3' extension using a high fidelity DNA polymerase. These copies are isothermally amplified to create clonal clusters of ~1,000 copies each, ready for sequencing.

Cluster generation reagents are provided in a pre-mixed, 96-well plate format that requires minimal reagent preparation. The kit also includes reagents for cluster resynthesis of the reverse strand, regenerated by bridge amplification within the paired-end flow cell. After resynthesis of the reverse strand, the original forward strand is cleaved and the reverse strand is sequenced for the second read.

1999年，Illumina只是一家擁有25人的初創(chuàng)公司，主要銷(xiāo)售微陣列芯片(microarray chip)，這種芯片可用來(lái)檢測(cè)基因組上特定部位的重要變化。

2007年，Illumina宣布以6億美元收購(gòu)基因測(cè)序公司Solexa，從而進(jìn)軍基因測(cè)序市場(chǎng)。Solexa的基因測(cè)試技術(shù)較競(jìng)爭(zhēng)對(duì)手快百倍，且價(jià)格低廉。

2013年收購(gòu)了無(wú)創(chuàng)產(chǎn)前診斷公司Verinata Health。自2005年以來(lái)，Illumina在并購(gòu)領(lǐng)域的投資已超過(guò)12億美元。

2014年1月，Illumina發(fā)布了新款基因測(cè)序儀，可以準(zhǔn)確測(cè)出全基因組序列，而成本還不到1000美元

上海易匯生物科技有限公司于17年正式銷(xiāo)售Illumina公司基因芯片、二代測(cè)序NGS測(cè)序儀及相關(guān)測(cè)序試劑盒等產(chǎn)品

咨詢(xún)illumina MiSeq測(cè)序試劑盒等產(chǎn)品歡迎您致電 上海易匯生物科技有限公司：1850 1609 238張經(jīng)理

Illumina公司，致力于新一代測(cè)序和芯片技術(shù)的生產(chǎn)與開(kāi)發(fā)，提供的產(chǎn)品與應(yīng)用資訊。Illumina公司創(chuàng)立于1998年4月，是遺傳變異和生物學(xué)功能分析領(lǐng)域的優(yōu)秀的產(chǎn)品、技術(shù)和服務(wù)供應(yīng)商。通過(guò)幫助客戶(hù)加快實(shí)現(xiàn)生物信息的采集、分析和應(yīng)用，來(lái)改善人類(lèi)健康。

As a startup, Illumina aspired to transform human health. Our initial products enabled researchers to explore DNA at an entirely new scale, helping them create the first map of gene variations associated with health, disease, and drug response. Every breakthrough opened up a new world, and showed us how much further there is to go

While the rate of progress is accelerating exponentially, we are only beginning to understand the clinical significance of the genome. What causes a cancer cell to mutate? What is the origin of a puzzling disease? Is it possible to prevent the next outbreak? Or safeguard the world’s food supply? These are just a few of the challenges that inspire us to push the boundaries of our imagination

Today we are a global leader in genomics – an industry at the intersection of biology and technology. At the most fundamental level, we enable our customers to read and understand genetic variations. We strive to make our solutions increasingly simple, more accessible, and always reliable. As a result, discoveries that were unimaginable even a few years ago are now becoming routine – and are making their way into patient treatment.

We now have the ability to sequence at an unprecedented scale. Collectively, this will give us a much deeper understanding of genetics than ever before. We will begin to truly unlock the power of the genome. These advances will trigger a fundamental shift in healthcare and beyond. Medicine will continue to become more preventive and more precise. We will be healthier, longer. We have only just begun.

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics

Illumina 測(cè)序試劑盒 PE-401-3001